OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 04:03:49 2024-05-02 EDT | ||
| 6.27 EUR / 6.28 EUR | +4.24% |
|
| 1 month | +32.89% | ||
| 3 months | +37.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 6.24 | +3.65% | 0 |
| 24-04-30 | 6.02 | +0.17% | 0 |
| 24-04-29 | 6.01 | -0.33% | 0 |
| 24-04-26 | 6.03 | +0.67% | 0 |
| 24-04-25 | 5.99 | +14.75% | 0 |
Delayed Quote Börse Stuttgart
Last update May 02, 2024 at 03:35 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR95R1 |
| ISIN | DE000HR95R17 |
| Date issued | 2021-08-10 |
| Strike | 6,867 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.65 € |
|---|---|
| Lowest since issue | 2.18 € |
| Spread | 0.01 € |
| Spread % | 0.16% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
164.3
USD
Spread / Average Target
+8.09%
- Stock Market
- Certificates
- Certificat
